These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 31628561)

  • 21. Comparison of locoregional versus extended locoregional radiation volumes for patients with nonmetastatic gastro-esophageal junction carcinomas.
    Wang J; Milton DR; He L; Komaki R; Liao Z; Crane CH; Minsky BD; Thall PF; Lin SH
    J Thorac Oncol; 2015 Mar; 10(3):518-26. PubMed ID: 25695222
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Association Between Geographic Access to Cancer Care, Insurance, and Receipt of Chemotherapy: Geographic Distribution of Oncologists and Travel Distance.
    Lin CC; Bruinooge SS; Kirkwood MK; Olsen C; Jemal A; Bajorin D; Giordano SH; Goldstein M; Guadagnolo BA; Kosty M; Hopkins S; Yu JB; Arnone A; Hanley A; Stevens S; Hershman DL
    J Clin Oncol; 2015 Oct; 33(28):3177-85. PubMed ID: 26304878
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Chemoresponse after non-curative gastrectomy for M1 gastric cancer.
    Shin HB; Lee SH; Son YG; Ryu SW; Sohn SS
    World J Surg Oncol; 2015 Jan; 13():13. PubMed ID: 25634223
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A reliable risk score for stage IV esophagogastric cancer.
    Blank S; Lordick F; Dobritz M; Grenacher L; Burian M; Langer R; Roth W; Schaible A; Becker K; Bläker H; Sisic L; Stange A; Compani P; Schulze-Bergkamen H; Jäger D; Büchler M; Siewert JR; Ott K
    Eur J Surg Oncol; 2013 Aug; 39(8):823-30. PubMed ID: 23375470
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Early Interdisciplinary Supportive Care in Patients With Previously Untreated Metastatic Esophagogastric Cancer: A Phase III Randomized Controlled Trial.
    Lu Z; Fang Y; Liu C; Zhang X; Xin X; He Y; Cao Y; Jiao X; Sun T; Pang Y; Wang Y; Zhou J; Qi C; Gong J; Wang X; Li J; Tang L; Shen L
    J Clin Oncol; 2021 Mar; 39(7):748-756. PubMed ID: 33417481
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Survival Benefit of Additional Surgery After Non-curative Endoscopic Submucosal Dissection for Early Gastric Cancer: A Propensity Score Matching Analysis.
    Suzuki S; Gotoda T; Hatta W; Oyama T; Kawata N; Takahashi A; Yoshifuku Y; Hoteya S; Nakagawa M; Hirano M; Esaki M; Matsuda M; Ohnita K; Yamanouchi K; Yoshida M; Dohi O; Takada J; Tanaka K; Yamada S; Tsuji T; Ito H; Hayashi Y; Shimosegawa T
    Ann Surg Oncol; 2017 Oct; 24(11):3353-3360. PubMed ID: 28795364
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Long-term outcomes and prognostic factors with non-curative endoscopic submucosal dissection for gastric cancer in elderly patients aged ≥ 75 years.
    Toya Y; Endo M; Nakamura S; Akasaka R; Yanai S; Kawasaki K; Koeda K; Eizuka M; Fujita Y; Uesugi N; Ishida K; Sugai T; Matsumoto T
    Gastric Cancer; 2019 Jul; 22(4):838-844. PubMed ID: 30560475
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Hospital Surgical Volume and 3-Year Mortality in Severe Prognosis Cancers: A Population-Based Study Using Cancer Registry Data.
    Taniyama Y; Tabuchi T; Ohno Y; Morishima T; Okawa S; Koyama S; Miyashiro I
    J Epidemiol; 2021 Jan; 31(1):52-58. PubMed ID: 31932528
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Trimodality therapy for esophageal cancer at high volume facilities is associated with improved postoperative outcomes and overall survival.
    Haque W; Verma V; Butler EB; Teh BS
    Dis Esophagus; 2019 Apr; 32(4):. PubMed ID: 30052835
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Safety, efficacy, and long-term follow-up evaluation of perioperative epirubicin, Cisplatin, and capecitabine chemotherapy in esophageal resection for adenocarcinoma.
    van der Sluis PC; Ubink I; van der Horst S; Boonstra JJ; Voest EE; Ruurda JP; Borel Rinkes IH; Wiezer MJ; Schipper ME; Siersema PD; Los M; Lolkema MP; van Hillegersberg R
    Ann Surg Oncol; 2015 May; 22(5):1555-63. PubMed ID: 25564156
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Tumor stage after neoadjuvant chemotherapy determines survival after surgery for adenocarcinoma of the esophagus and esophagogastric junction.
    Davies AR; Gossage JA; Zylstra J; Mattsson F; Lagergren J; Maisey N; Smyth EC; Cunningham D; Allum WH; Mason RC
    J Clin Oncol; 2014 Sep; 32(27):2983-90. PubMed ID: 25071104
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Impact of external-beam radiation therapy on outcomes among patients with resected gastric cancer: a multi-institutional analysis.
    Ejaz A; Spolverato G; Kim Y; Squires MH; Poultsides G; Fields R; Bloomston M; Weber SM; Votanopoulos K; Worhunsky DJ; Swords D; Jin LX; Schmidt C; Acher AW; Saunders N; Cho CS; Herman JM; Maithel SK; Pawlik TM
    Ann Surg Oncol; 2014 Oct; 21(11):3412-21. PubMed ID: 24845728
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Intensity-modulated radiotherapy at high-volume centers improves survival in patients with esophageal adenocarcinoma receiving trimodality therapy.
    Yang GQ; Mhaskar R; Rishi A; Naghavi AO; Frakes JM; Almhanna K; Fontaine J; Pimiento JM; Hoffe SE
    Dis Esophagus; 2019 Aug; 32(8):. PubMed ID: 30597022
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Real-World Outcomes and Factors Associated With the Second-Line Treatment of Patients With Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma.
    Barzi A; Hess LM; Zhu YE; Liepa AM; Sugihara T; Beyrer J; Chao J
    Cancer Control; 2019; 26(1):1073274819847642. PubMed ID: 31056940
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Rilotumumab plus epirubicin, cisplatin, and capecitabine as first-line therapy in advanced MET-positive gastric or gastro-oesophageal junction cancer (RILOMET-1): a randomised, double-blind, placebo-controlled, phase 3 trial.
    Catenacci DVT; Tebbutt NC; Davidenko I; Murad AM; Al-Batran SE; Ilson DH; Tjulandin S; Gotovkin E; Karaszewska B; Bondarenko I; Tejani MA; Udrea AA; Tehfe M; De Vita F; Turkington C; Tang R; Ang A; Zhang Y; Hoang T; Sidhu R; Cunningham D
    Lancet Oncol; 2017 Nov; 18(11):1467-1482. PubMed ID: 28958504
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Mortality differences by surgical volume among patients with stomach cancer: a threshold for a favorable volume-outcome relationship.
    Choi H; Yang SY; Cho HS; Kim W; Park EC; Han KT
    World J Surg Oncol; 2017 Jul; 15(1):134. PubMed ID: 28716145
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Association Between Waiting Time from Diagnosis to Treatment and Survival in Patients with Curable Gastric Cancer: A Population-Based Study in the Netherlands.
    Brenkman HJF; Visser E; van Rossum PSN; Siesling S; van Hillegersberg R; Ruurda JP
    Ann Surg Oncol; 2017 Jul; 24(7):1761-1769. PubMed ID: 28353020
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Institutional Enrollment and Survival Among NSCLC Patients Receiving Chemoradiation: NRG Oncology Radiation Therapy Oncology Group (RTOG) 0617.
    Eaton BR; Pugh SL; Bradley JD; Masters G; Kavadi VS; Narayan S; Nedzi L; Robinson C; Wynn RB; Koprowski C; Johnson DW; Meng J; Curran WJ
    J Natl Cancer Inst; 2016 Sep; 108(9):. PubMed ID: 27206636
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Patient education-level affects treatment allocation and prognosis in esophageal- and gastroesophageal junctional cancer in Sweden.
    Linder G; Sandin F; Johansson J; Lindblad M; Lundell L; Hedberg J
    Cancer Epidemiol; 2018 Feb; 52():91-98. PubMed ID: 29278841
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Is Centralization Needed for Esophageal and Gastric Cancer Patients With Low Operative Risk?: A Nationwide Study.
    Pasquer A; Renaud F; Hec F; Gandon A; Vanderbeken M; Drubay V; Caranhac G; Piessen G; Mariette C;
    Ann Surg; 2016 Nov; 264(5):823-830. PubMed ID: 27429033
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.